Gilead Is Looking Good

Is it time to buy Gilead Sciences?

The upcoming transits to the First-Trade horoscope, as well as other Gilead dynamics, identify this stock as a good trading candidate now.

Gilead transits to First-Trade
Transits to the Gilead Sciences First-Trade Horoscope

Gilead Sciences, Inc. (NASDAQ – GILD) is a research-based biopharmaceutical company.

Headquartered in Foster City, California, Gilead discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and elsewhere around the world.

The company’s products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases.

Gilead also provides Yescarta, a chimeric antigen receptor T cell therapy for adult patients with relapsed or refractory large B-cell lymphoma; and Zydelig, a kinase inhibitor.

It makes Letairis, an oral formulation of an endothelin receptor antagonist for pulmonary arterial hypertension; Ranexa, a tablet to treat chronic angina; and AmBisome, an antifungal agent to treat serious invasive fungal infections.

In addition, the company offers its products under a variety of other brand names. They include Cayston, Emtriva, Hepsera, Sovaldi, and Tybost.

Gildead also develops product candidates for the treatment of viral diseases, inflammatory and fibrotic diseases, and oncology.

The company markets its products through its commercial teams. It also works in conjunction with third-party distributors and corporate partners.

Positive Transits for Gilead

Transiting Saturn conjoining the Gilead First-Trade Sun could provide a more favorable entry point for a long position here. While Saturn is associated with contraction, it can provide a basis for further price advancement in a case like this.

And that’s not all.

The potential for higher prices ahead and an increase in speculative energy is indicated by transiting Neptune conjoining the First-Trade Ascendant.

On top of that, transiting Venus is forming a quincunx to First-Trade Neptune. That’s very nice for a drug company!

In other words, this looks like a solid setup for a good buying opportunity for this stock.

Yesterday we added Gilead to our watch list for our members at FinancialCyclesWeekly.com.

Our astro-trading trend chart shows why. Note the recent price gap upward.

Geocentric planetary price lines for Mars and Jupiter in the eighth harmonic help reveal the trading structure for Gilead.

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.